Keyphrases
ALVAC
100%
Carcinoembryonic Antigen
80%
Adenocarcinoma
80%
Virus
32%
Immune Response
32%
Clinical Response
32%
Canarypox Virus
20%
Treatment Duration
16%
B7-1
16%
Phase I Trial
16%
Tumor
16%
Increased Dose
16%
Immunization
16%
Optimal Dose
16%
Vaccine Adverse Events
16%
T Cell Assay
16%
T Cell Response
16%
Tumor Cells
16%
Intramuscular Injection
16%
Experimental Therapeutics
16%
Medicine and Dentistry
B7 Antigen
100%
Adenocarcinoma
80%
Carcinoembryonic Antigen
80%
Immune Response
32%
Canarypox Virus
20%
T-Cell Response
16%
Side Effect
16%
Optimal Drug Dose
16%
Phase I Trials
16%
Malignant Neoplasm
16%
Tumor Cell
16%
In Vitro
16%
Neoplasm
16%
Experimental Therapy
16%
Intramuscular Injection
16%
T Cell
16%
Pharmacology, Toxicology and Pharmaceutical Science
B7 Antigen
100%
Carcinoembryonic Antigen
80%
Adenocarcinoma
80%
Neoplasm
32%
Canarypox Virus
20%
Side Effect
16%
Intramuscular Injection
16%
Malignant Neoplasm
16%
Phase I Trials
16%